Dr. Bazarbachi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1400 Pelham Pkwy S
Bronx, NY 10461- Is this information wrong?
Education & Training
Jacobi Medical Center/North Central Bronx HospitalResidency, Internal Medicine, 2020
Dana-Farber Cancer InstitutePost-Doctoral Fellowship, Molecular Oncology, 2019 - 2020
American University of Beirut Faculty of MedicineClass of 2018
Certifications & Licensure
NY State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- TCL-150 Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma.Hiba Narvel, Abdul-Hamid Bazarbachi, Daniel Reef, Riya Patel, Astha Thakkar, Sumaira Zareef, Alyssa de Castro, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Kira Gri...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Oct 1
- 11 citationsIgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.Abdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, Anil Aktas Samur, Zachary R. Hunter, Masood A. Shammas, Jill Corre, Mariateresa Fulciniti, Kenneth C. Ander...> ;Blood. 2021 Nov 18
- 5 citationsHigh seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.Shapiro, L., Thakkar, A., Gali, R., Gonzalez-Lugo, J., Bazarbachi, A., Rahman, S., Pradhan, K., Fehn, K., Abreu, M., Kornblum, N., Gritsman, K., Goldfinger, M., Shastr...> ;Leukemia & Lymphoma. 2022 Oct 1
- Join now to see all
Journal Articles
- Allogeneic transplant for FLT3-ITD mutated AML: advances and challengesBazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A, Therapeutic Advances in Hematology, 7/2019
- A Phase 2 Study of Hyper-CVAD plus Ofatumumab as Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated resultsBazarbachi AH, Yilmaz M, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Short N, Sasaki K, Issa G, Koller P, Schroeder H, Kadia T, Verstovsek S, D..., Journal of Clinical Oncology, 5/2018
- How I treat and monitor non-transfusion-dependent thalassaemiaBazarbachi AH, Moukhadder H, Bou Fakhredin R, Roumi J, Chaya B, Taher A, Haematologica, 3/2017
- Join now to see all
Abstracts/Posters
- Allogeneic stem cell transplantation (allo-SCT) with sequential conditioning in patients with primary refractory or relapsed adult acute lymphoblastic leukemia: a repo...Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D, Ganser A, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Giebel S, Nagl..., European Society for Blood and Marrow Transplantation, Frankfurt, DEU, 3/2019
- Azacitidine (AZA) For Prophylaxis or Pre-emptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell TransplantationMarini C, Brissot E, Bazarbachi AH, Dulery R, Sestili S, Battipaglia G, Mediavilla C, Paviglianiti A, Belhocine R, Isnard F, Lapusan S, Adaeva R, Vekhoff A, Ledraa T, ..., European Society for Blood and Marrow Transplantation, Frankfurt, DEU, 3/2019
- A Phase 2 Study of Hyper-CVAD plus Ofatumumab as Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated resultsBazarbachi AH, Yilmaz M, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Short N, Sasaki K, Issa G, Koller P, Schroeder H, Kadia T, Verstovsek S, D..., American Society of Clinical Oncology, Chicago, IL, USA, 6/2018
Hospital Affiliations
NYC Health + Hospitals / JacobiBronx, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
